Commentary Open Access
Volume 1 | Issue 2 | DOI: https://doi.org/10.46439/breastcancer.1.009
Weaknesses with research models and disparities: how PDX models strengthen both
Khoa Nguyen1,*, Maryl K Wright1, Madlin Alzoubi1, Thomas Cheng1, Margarite D Matossian1, Bridgette M Collins-Burow1, Matthew E Burow1,*
- 1Section of Hematology and Oncology, Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA
Corresponding Author
Khoa Nguyen, KNguyen11@tulane.edu,
Matthew E Burow, mburow@tulane.edu
Received Date: October 10, 2021
Accepted Date: December 14, 2021
Nguyen K, Wright MK, Alzoubi M, Cheng T, Matossian MD, Collins- Burow BM, et al. Weaknesses with research models and disparities: how PDX models strengthen both. J Breast Cancer Res 2021; 1(2):40-42.
Copyright: © 2021 Nguyen K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Breast cancer: an up-date review
Breast cancer is the second most common cancer in the world and the most common cancer among women. The most common presenting symptoms are a painless subareolar lump, nipple retraction, and bleeding from the nipple.
Weaknesses with research models and disparities: how PDX models strengthen both
In the manuscript titled Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model, our research group generated a novel PDX model TU-BcX-2K1 (2K1 for short) by implanting a piece of primary patient tumor derived from a pre-neoadjuvant 59-year-old Black woman with invasive ductal carcinoma, triple negative subtype, into SCID/Beige mice.
Breast cancer prognostic tests: Taking us one step closer to personalized treatment
Breast cancer is the most common cancer in women worldwide, with the highest mortality rates. While breast tumors can have heterogeneous biology, the mutational burden/genomic alterations, etc, are relatively less when compared to other malignancies like pancreatic cancer or glioblastomas, rendering breast tumors comparatively less aggressive.